Crescent Biopharma, Inc. (CBIO)

NCM – Real Time Price. Currency in USD

18.46

-0.06 (-0.32%)

At close: May 12, 2026, 4:00 PM EDT

18.20

-0.26 (-1.41%)

After-hours: May 12, 2026, 7:08 PM EDT

06.05.2026

Crescent Biopharma to Present at May Investor Conferences

WALTHAM, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in May: BofA Securities 2026 Healthcare Conference, fireside chat on Wednesday, May 13, 2026 at 4:20 p.m.

29.04.2026

Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights

ASCEND Phase 1/2 global clinical trial ongoing, evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients; first ADC combination trial with CR-001 on track to initiate in second half of 2026 Phase 1/2 trial of CR-003, an ITGB6-targeted ADC, ongoing in China CR-002, a PD-L1-targeted ADC, on track to enter the clinic in second half of 2026 Multiple key clinical data readouts anticipated beginning in Q1 2027 WALTHAM, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced financial results for the first quarter ended March 31, 2026 and recent business highlights.

24.04.2026

Crescent Biopharma Announces Grants of Inducement Awards

WALTHAM, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 12,525 shares of the Company's ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on April 23, 2026 and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).

27.03.2026

Crescent Biopharma Announces Grants of Inducement Awards

WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 35,325 shares of the Company's ordinary shares to three non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on March 26, 2026 and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).

06.03.2026

Crescent Biopharma Announces Grants of Inducement Awards

WALTHAM, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 45,675 shares of the Company's ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on March 5, 2026 and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).

26.02.2026

Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Established partnership with Kelun-Biotech expanding pipeline and accelerating combination strategy with CR-001, PD-1 x VEGF bispecific antibody, and multiple ADCs

23.02.2026

Crescent Biopharma to Present at March Investor Conferences

WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in March:

Videos

No Data

There is no data to display

Press releases

29.04.2026

Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights

24.04.2026

Crescent Biopharma Announces Grants of Inducement Awards

27.03.2026

Crescent Biopharma Announces Grants of Inducement Awards

06.03.2026

Crescent Biopharma, Inc. (CBIO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Crescent Biopharma, Inc. (CBIO)

Crescent Biopharma to Present at May Investor Conferences

Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Crescent Biopharma to Present at March Investor Conferences

Videos

No Data

Press releases

Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma to Present at May Investor Conferences

Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Crescent Biopharma to Present at March Investor Conferences

Videos

No Data

Press releases

Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Announces Grants of Inducement Awards

Search stocks

Crescent Biopharma, Inc. (CBIO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Crescent Biopharma, Inc. (CBIO)

Crescent Biopharma to Present at May Investor Conferences

Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Crescent Biopharma to Present at March Investor Conferences

Videos

No Data

Press releases

Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma to Present at May Investor Conferences

Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Crescent Biopharma to Present at March Investor Conferences

Videos

No Data

Press releases

Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Announces Grants of Inducement Awards